17,261 trials
Autosomal Dominant Polycystic Kidney Disease
Primary: Maximum Observed Plasma Concentration (Cmax) of Lixivaptan in ADPKD Patients — 656.8; 190.9; 681.3; 156.9 ng/mL
Head and Neck Squamous Cell Carcinoma · Breast Cancer · Sarcoma
Primary: Number of Subjects With Treatment-emergent Adverse Events (TEAEs) — 4; 5; 1; 15 Participants
Loss of Chromosome 17p · Recurrent Plasma Cell Myeloma
Primary: The Number of Participants Who Experienced Dose Limiting Toxicities. Maximum Tolerated Dose (MTD) of Ixazomib Citrate and Idasanutlin in Combination With Dexamethasone…
Dry Eye Disease
Primary: Total Ocular Surface Disease Index — 21.17; 21.36 score on a scale — p=0.967
Myopia
Primary: Diameter of the Pupil Measured With a Neuroptix Pupillometer — 4.9; 5.1; 5.9; 5.9 millimeters — p=0.002
Fibrodysplasia Ossificans Progressiva
Primary: Period 1: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs — 24; 20; 2; 4 Participants
Diamond Blackfan Anemia · Blackfan Diamond Syndrome · DBA
Primary: Response to Leucine in Transfusion Dependent Patients With Diamond Blackfan Anemia — 2; 5; 36; 0 Participants
COVID-19 · SARS-CoV 2
Primary: Percent of Healthcare Workers Testing Positive for COVID-19. — 0; 0 percentage of healthcare workers
Tobacco Use Disorder
Primary: Cigarettes Per Day (CPD) — 25.28; 19.95; 17.74 cigarettes per day — p=<0.0001
Chronic Kidney Diseases
Primary: Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Week 12 — 6.79; -0.92 mL/min/1.73 m^2 — p=<0.0001
Hormone-Resistant Prostate Cancer · Metastatic Malignant Neoplasm in the Bone · Metastatic Malignant Neoplasm in the Soft Tissues
Primary: Incidence of Adverse Events, Using the National Cancer Common Terminology Criteria, Version 4 — 117; 173; 163; 225 Adverse events
Waldenstrom Macroglobulinemia
Primary: Overall Response Rate (ORR) According to the Modified Sixth International Workshop on Waldenstrom's Macroglobulinemia (IWWM) Criteria — 87.5 percentage of participants
Chronic Lymphocytic Leukemia · Small Lymphocytic Leukemia
Primary: Phase I: Maximum Tolerated Dose (MTD) — NA mg
Dermatitis, Atopic
Primary: Percentage Change From Baseline in the Eczema Area and Severity Index (EASI) Score at Week 16 — -12.3; -37.9 Percent change — p=0.1492
Acute Appendicitis
Primary: Number of Children With an Accurate Diagnosis of Appendicitis. — 6; 15; 1; 13 Participants